Literature DB >> 18042148

The epigenome of testicular germ cell tumors.

Guro E Lind1, Rolf I Skotheim, Ragnhild A Lothe.   

Abstract

Gene expression is tightly regulated in normal cells, and epigenetic changes disturbing this regulation are a common mechanism in the development of cancer. Testicular germ cell tumor (TGCT) is the most common malignancy among young males and can be classified into two main histological subgroups: seminomas, which are basically devoid of DNA methylation, and nonseminomas, which in general have methylation levels comparable with other tumor tissues, as shown by restriction landmark genome scanning (RLGS). In general, DNA methylation seems to increase with differentiation, and among the nonseminomas, the pluripotent and undifferentiated embryonal carcinomas harbor the lowest levels of DNA promoter hypermethylation, whereas the well-differentiated teratomas display the highest. In this regard, TGCTs resemble the early embryogenesis. So far, only a limited number of tumor suppressor genes have been shown to be inactivated by DNA promoter hypermethylation in more than a minor percentage of TGCTs, including MGMT, SCGB3A1, RASSF1A, HIC1, and PRSS21. In addition, imprinting defects, DNA hypomethylation of testis/cancer associated genes, and the presence of unmethylated XIST are frequent in TGCTs. Aberrant DNA methylation has the potential to improve current diagnostics by noninvasive testing and might also serve as a prognostic marker for treatment response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18042148     DOI: 10.1111/j.1600-0463.2007.apm_660.xml.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  24 in total

Review 1.  Clinical significance of the interaction between non-coding RNAs and the epigenetics machinery: challenges and opportunities in oncology.

Authors:  Beatriz M Maia; Rafael M Rocha; George A Calin
Journal:  Epigenetics       Date:  2013-10-11       Impact factor: 4.528

2.  DNA Methylation and Flavonoids in Genitourinary Cancers.

Authors:  Neelam Mukherjee; Addanki P Kumar; Rita Ghosh
Journal:  Curr Pharmacol Rep       Date:  2015-04-01

3.  Molecular genetics of testicular germ cell tumors.

Authors:  Yuri Sheikine; Elizabeth Genega; Jonathan Melamed; Peng Lee; Victor E Reuter; Huihui Ye
Journal:  Am J Cancer Res       Date:  2012-02-15       Impact factor: 6.166

4.  Incorporating DNA Methyltransferase Inhibitors (DNMTis) in the Treatment of Genitourinary Malignancies: A Systematic Review.

Authors:  Michal Chovanec; Fadi Taza; Maitri Kalra; Noah Hahn; Kenneth P Nephew; Michael J Spinella; Costantine Albany
Journal:  Target Oncol       Date:  2018-02       Impact factor: 4.493

Review 5.  Epigenetics and its role in male infertility.

Authors:  Rima Dada; Manoj Kumar; Rachel Jesudasan; Jose Luis Fernández; Jaime Gosálvez; Ashok Agarwal
Journal:  J Assist Reprod Genet       Date:  2012-03       Impact factor: 3.412

6.  microRNA-199a-3p, DNMT3A, and aberrant DNA methylation in testicular cancer.

Authors:  Bi-Feng Chen; Shen Gu; Yick-Keung Suen; Lu Li; Wai-Yee Chan
Journal:  Epigenetics       Date:  2013-08-19       Impact factor: 4.528

Review 7.  DNA methylation of cancer genome.

Authors:  Hoi-Hung Cheung; Tin-Lap Lee; Owen M Rennert; Wai-Yee Chan
Journal:  Birth Defects Res C Embryo Today       Date:  2009-12

8.  LINE-1 methylation is inherited in familial testicular cancer kindreds.

Authors:  Lisa Mirabello; Sharon A Savage; Larissa Korde; Shahinaz M Gadalla; Mark H Greene
Journal:  BMC Med Genet       Date:  2010-05-17       Impact factor: 2.103

Review 9.  DNA Methylation and Urological Cancer, a Step Towards Personalized Medicine: Current and Future Prospects.

Authors:  Javier C Angulo; Jose I López; Santiago Ropero
Journal:  Mol Diagn Ther       Date:  2016-12       Impact factor: 4.074

10.  Pediatric germ cell tumors and maternal vitamin supplementation: a Children's Oncology Group study.

Authors:  Kimberly J Johnson; Jenny N Poynter; Julie A Ross; Leslie L Robison; Xiao Ou Shu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-09-15       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.